Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
University of Arizona
Headquarters: Tucson, AZ, United States of America
Website: http://www.arizona.edu
Year Founded: 1885
Status: Non-biopharma
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Mar 26, 2025
Discovery & Translation
Science Spotlight: New insight into LAG3’s checkpoint function
BioCentury’s roundup of translational innovations also includes a blood-based T cell assay for T1D, a degrader using a new E3 ligase, and papers from newcos
BioCentury | Aug 24, 2023
Finance
Aug. 23 Quick Takes: CVS launches biosimilar subsidiary
Plus: Foundery raising $160M for first fund, Apellis shares bounce back and updates from Cellares, Agenus, Pfizer, Astellas and more
BioCentury | Jan 3, 2022
Product Development
What’s next for voltage-gated sodium channel blockers
Companies dial in subtype selectivity, explore new modalities, and move to more homogeneous trial populations
BioCentury | Dec 22, 2021
Emerging Company Profile
Clade: immune-cloaked, iPSC-derived cell therapies
Syncona’s first allogeneic cell therapy investment goes to Clade, led by Sana and CRISPR Therapeutics co-founder Cowan
BioCentury | Nov 13, 2021
Discovery & Translation
Repare identifies new BRCA synthetic lethal relationship; plus Immune-Onc, Acuitas and more
BioCentury’s roundup of translational news
BioCentury | Jan 30, 2021
Distillery Therapeutics
Inhibition of fungal splicing factor PRPF8 for cryptococcal infection
DISEASE CATEGORY: Infectious disease
INDICATION: Fungal infection Small molecule inhibitors of a Cryptococcus spp. intein-containing intron splicing factor PRPF8 could treat infections by
INDICATION: Fungal infection Small molecule inhibitors of a Cryptococcus spp. intein-containing intron splicing factor PRPF8 could treat infections by
BioCentury | Sep 19, 2020
Politics, Policy & Law
What it will take to get to mass asymptomatic screening for COVID-19
A look at the barriers to mass asymptomatic testing, and the path to removing them
BioCentury | Jul 25, 2019
Distillery Therapeutics
A benzoylphenylurea-based stabilizer of TERT G-quadruplex DNA for prostate cancer
BioCentury | Apr 26, 2019
Emerging Company Profile
ProNeurogen: Angiotensin peptides for vascular cognitive impairment
ProNeurogen is tackling vascular cognitive impairment with angiotensin peptides
Items per page:
1 - 10 of 105